vs
EXACT SCIENCES CORP（EXAS）与FRESH DEL MONTE PRODUCE INC（FDP）财务数据对比。点击上方公司名可切换其他公司
FRESH DEL MONTE PRODUCE INC的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.0B vs $878.4M），FRESH DEL MONTE PRODUCE INC净利率更高（3.2% vs -9.8%，领先13.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 0.6%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-17.2M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -4.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
鲜德尔蒙农产品公司是全球领先的垂直一体化生鲜及鲜切果蔬、加工果蔬生产、分销及营销企业，注册地位于开曼群岛乔治敦，美国行政总部设在佛罗里达州科勒尔盖布尔斯塞维利亚大道241号。
EXAS vs FDP — 直观对比
营收规模更大
FDP
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出22.5%
0.6%
净利率更高
FDP
高出13.0%
-9.8%
自由现金流更多
EXAS
多$137.6M
$-17.2M
两年增速更快
EXAS
近两年复合增速
-4.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.0B |
| 净利润 | $-86.0M | $32.3M |
| 毛利率 | 70.1% | 10.4% |
| 营业利润率 | -9.4% | 4.5% |
| 净利率 | -9.8% | 3.2% |
| 营收同比 | 23.1% | 0.6% |
| 净利润同比 | 90.1% | 59.1% |
| 每股收益（稀释后） | $-0.45 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFDP
| Q4 25 | $878.4M | $1.0B | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $1.2B | ||
| Q1 25 | $706.8M | $1.1B | ||
| Q4 24 | $713.4M | $1.0B | ||
| Q3 24 | $708.7M | $1.0B | ||
| Q2 24 | $699.3M | $1.1B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASFDP
| Q4 25 | $-86.0M | $32.3M | ||
| Q3 25 | $-19.6M | $-29.1M | ||
| Q2 25 | $-1.2M | $56.8M | ||
| Q1 25 | $-101.2M | $31.1M | ||
| Q4 24 | $-864.6M | $20.3M | ||
| Q3 24 | $-38.2M | $42.1M | ||
| Q2 24 | $-15.8M | $53.6M | ||
| Q1 24 | $-110.2M | $26.1M |
毛利率EXASFDP
| Q4 25 | 70.1% | 10.4% | ||
| Q3 25 | 68.6% | 7.9% | ||
| Q2 25 | 69.3% | 10.2% | ||
| Q1 25 | 70.8% | 8.4% | ||
| Q4 24 | 69.0% | 6.8% | ||
| Q3 24 | 69.4% | 9.2% | ||
| Q2 24 | 69.8% | 9.9% | ||
| Q1 24 | 70.0% | 7.4% |
营业利润率EXASFDP
| Q4 25 | -9.4% | 4.5% | ||
| Q3 25 | -3.0% | -2.1% | ||
| Q2 25 | -0.3% | 5.8% | ||
| Q1 25 | -13.6% | 4.1% | ||
| Q4 24 | -122.8% | 3.0% | ||
| Q3 24 | -5.6% | 5.3% | ||
| Q2 24 | -3.8% | 6.0% | ||
| Q1 24 | -16.7% | 4.0% |
净利率EXASFDP
| Q4 25 | -9.8% | 3.2% | ||
| Q3 25 | -2.3% | -2.8% | ||
| Q2 25 | -0.1% | 4.8% | ||
| Q1 25 | -14.3% | 2.8% | ||
| Q4 24 | -121.2% | 2.0% | ||
| Q3 24 | -5.4% | 4.1% | ||
| Q2 24 | -2.3% | 4.7% | ||
| Q1 24 | -17.3% | 2.4% |
每股收益（稀释后）EXASFDP
| Q4 25 | $-0.45 | $0.67 | ||
| Q3 25 | $-0.10 | $-0.61 | ||
| Q2 25 | $-0.01 | $1.18 | ||
| Q1 25 | $-0.54 | $0.64 | ||
| Q4 24 | $-4.69 | $0.41 | ||
| Q3 24 | $-0.21 | $0.88 | ||
| Q2 24 | $-0.09 | $1.12 | ||
| Q1 24 | $-0.60 | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $35.7M |
| 总债务越低越好 | — | $176.2M |
| 股东权益账面价值 | $2.4B | $2.0B |
| 总资产 | $5.9B | $3.1B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资EXASFDP
| Q4 25 | $964.7M | $35.7M | ||
| Q3 25 | $1.0B | $97.2M | ||
| Q2 25 | $858.4M | $85.5M | ||
| Q1 25 | $786.2M | $34.4M | ||
| Q4 24 | $1.0B | $32.6M | ||
| Q3 24 | $1.0B | $50.8M | ||
| Q2 24 | $946.8M | $37.8M | ||
| Q1 24 | $652.1M | $42.2M |
总债务EXASFDP
| Q4 25 | — | $176.2M | ||
| Q3 25 | — | $176.7M | ||
| Q2 25 | — | $205.2M | ||
| Q1 25 | — | $237.4M | ||
| Q4 24 | — | $248.9M | ||
| Q3 24 | — | $274.8M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $405.8M |
股东权益EXASFDP
| Q4 25 | $2.4B | $2.0B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.4B | $2.0B | ||
| Q4 24 | $2.4B | $2.0B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $2.0B | ||
| Q1 24 | $3.1B | $1.9B |
总资产EXASFDP
| Q4 25 | $5.9B | $3.1B | ||
| Q3 25 | $5.9B | $3.1B | ||
| Q2 25 | $5.8B | $3.2B | ||
| Q1 25 | $5.7B | $3.2B | ||
| Q4 24 | $5.9B | $3.1B | ||
| Q3 24 | $6.7B | $3.2B | ||
| Q2 24 | $6.7B | $3.1B | ||
| Q1 24 | $6.4B | $3.2B |
负债/权益比EXASFDP
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.09× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $10.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-17.2M |
| 自由现金流率自由现金流/营收 | 13.7% | -1.7% |
| 资本支出强度资本支出/营收 | 3.6% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 0.34× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $181.3M |
8季度趋势，按日历期对齐
经营现金流EXASFDP
| Q4 25 | $151.7M | $10.9M | ||
| Q3 25 | $219.9M | $75.0M | ||
| Q2 25 | $89.0M | $113.1M | ||
| Q1 25 | $30.8M | $46.1M | ||
| Q4 24 | $47.1M | $-4.7M | ||
| Q3 24 | $138.7M | $43.5M | ||
| Q2 24 | $107.1M | $125.0M | ||
| Q1 24 | $-82.3M | $18.7M |
自由现金流EXASFDP
| Q4 25 | $120.4M | $-17.2M | ||
| Q3 25 | $190.0M | $60.9M | ||
| Q2 25 | $46.7M | $101.5M | ||
| Q1 25 | $-365.0K | $36.1M | ||
| Q4 24 | $10.7M | $-22.3M | ||
| Q3 24 | $112.6M | $30.1M | ||
| Q2 24 | $71.2M | $117.0M | ||
| Q1 24 | $-120.0M | $6.0M |
自由现金流率EXASFDP
| Q4 25 | 13.7% | -1.7% | ||
| Q3 25 | 22.3% | 6.0% | ||
| Q2 25 | 5.8% | 8.6% | ||
| Q1 25 | -0.1% | 3.3% | ||
| Q4 24 | 1.5% | -2.2% | ||
| Q3 24 | 15.9% | 3.0% | ||
| Q2 24 | 10.2% | 10.3% | ||
| Q1 24 | -18.8% | 0.5% |
资本支出强度EXASFDP
| Q4 25 | 3.6% | 2.8% | ||
| Q3 25 | 3.5% | 1.4% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 0.9% | ||
| Q4 24 | 5.1% | 1.7% | ||
| Q3 24 | 3.7% | 1.3% | ||
| Q2 24 | 5.1% | 0.7% | ||
| Q1 24 | 5.9% | 1.1% |
现金转化率EXASFDP
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.99× | ||
| Q1 25 | — | 1.48× | ||
| Q4 24 | — | -0.23× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 2.33× | ||
| Q1 24 | — | 0.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FDP
| Other | $482.7M | 47% |
| Gold Pineapples | $184.9M | 18% |
| Fresh Cut Fruit | $126.4M | 12% |
| Fresh Cut Vegetables | $69.3M | 7% |
| Avocados | $66.9M | 7% |
| Other Fruit Productsand Services | $26.1M | 3% |
| Non Tropical Fruit | $23.0M | 2% |
| Melons | $20.6M | 2% |
| Vegetables | $19.6M | 2% |
